A study published in Psychological Medicine found that a laxative drug, Prucalopride, improved executive function and memory in patients with depression. The research suggests that targeting serotonin receptors may help alleviate cognitive problems associated with depression.
A global study confirms mosquito nets reduce malaria cases by up to 68%, but highlights regional variations and the need for locally adapted control strategies. The researchers warn that relying on ITNs alone may not be enough, especially in areas with established insecticide resistance.
Researchers have found a potential new treatment for DHDDS-related disease by creating mini-brains from patients' cells and testing vitamin B3. The study showed significant improvements in patients' symptoms, including reduced tremors and increased energy levels.
A large-scale study found dozens of genetic mutations linked to cancer type and ancestry, improving survival predictions in breast and glioma cancers. Combining ancestry data with tumour analyses enhances prediction accuracy, particularly for pancreatic cancer patients.
Researchers found a copper-based compound significantly reduces toxic Alzheimer's proteins and improves long-term spatial memory in laboratory experiments. The treatment repairs the brain's waste-clearing pump, allowing it to clear out trapped toxic proteins and reduce amyloid buildup by 42%.
A retrospective cohort study found that menopausal hormone therapy significantly reduces the risk of low bone mineral density by 69% compared to non-users. This suggests that hormone therapy could be an effective way to prevent bone loss and lower fracture risks in women after menopause.
A study presented at ENDO 2026 found semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications. The results suggest that semaglutide may have beneficial effects on bone health in people with type 2 diabetes.
A study found that nearly 4 in 10 patients stopped GLP-1 medication within the first year and nearly two-thirds restarted therapy within two years. The researchers also identified sociodemographic, clinical, and provider-level predictors of discontinuation, including Medicaid or Medicare status, Black patients, and side effects.
The first real-world study of fezolinetant found the treatment improved hot flashes, depression, and anxiety in women with menopausal vasomotor symptoms. In a study of 656 women, fezolinetant significantly reduced hot flash symptoms and showed benefits similar to those seen in clinical trials.